The study objectiveis to evaluate clinical effectiveness of a phytopharmaceutical Vialissil® for treatment of patients with benign prostatic hyperplasia (BPH) and erectile dysfunction.Materials and methods. At the multi-specialty clinic “Family Doctor” (Saint Petersburg) 34 patients aged from 55 to 67 years (mean age 59.6 + 0.7 years) with BPH and concomitant erectile dysfunction without the need for surgical intervention were examined. All patients received previously prescribed symptomatic therapy for BPH and erectile dysfunction (a-adrenoblockers and phosphodiesterase type 5 inhibitors on demand). The treatment group included 18 patients who additionally received Vialissil® as capsules once a day for 30 days. The remaining 16 patients were the control group.Results.After treatment, intensity of general symptoms decreased more in the treatment group than in the control group (by 10 and 4 points, respectively). After the course of therapy, erectile function improved in both groups but only in the treatment group these dynamics were statistically significant. An increase in testosterone level was statistically significant only after combination therapy with Vialissil® (by 16.5 %), and blood level of biologically accessible (active) testosterone increased twofold.Conclusion.Combination therapy for BPH and erectile dysfunction including administration of the Vialissil® phytopharmaceutical more effectively decreases disease intensity compared to standard therapy.

No abstract

No abstract

No abstract

No abstract